Integration of Management Resources and Administrative Structure for the Regenerative Medicine-Related Business
First written in FY2021-Q1. 6 of 7 entries say "Restated". Latest entry: FY2025-H1.
1 other company's latest entry also says "Restated".
- FY2025-H1RestatedAnnual report
「The Company has also adopted a single segment, the regenerative medicine-related business.」
Operations continue under a single segment integrated into the regenerative medicine-related business. - FY2024-Q1RestatedAnnual report
「The Company has adopted a single segment, the regenerative medicine-related business.」
Operations continue under a single segment, with management resources and the management structure integrated into the regenerative medicine-related business. - FY2023-Q3RestatedAnnual report
「The Company has adopted a single segment, the regenerative medicine-related business.」
Operations continue under a single segment integrated into the regenerative medicine-related business. - FY2023-Q1RestatedAnnual report
「The Company has adopted a single segment, the regenerative medicine-related business.」
Operations continue under a single segment, with management resources and the management structure integrated into the regenerative medicine-related business. - FY2021RestatedAnnual report
「From the current fiscal year, we have changed to a single segment, the regenerative medicine-related business.」
Operations continue under a single regenerative medicine-related business segment, with the allocation of management resources and the management structure standardized. - FY2021-Q2RestatedAnnual report
「Previously, we had the regenerative medicine-related business and the consumer business as 2 reporting segments, but from the first quarter accounting period we have changed to a single segment, the regenerative medicine-related business.」
The reporting classification has remained a single regenerative medicine-related business segment since the first quarter accounting period. - FY2021-Q1First statedAnnual report
「In the consumer business, we discontinued the purchase and sale of facial-care devices in the previous fiscal year and now only manufacture and sell Signalift-brand cosmetics leveraging our expertise in regenerative medicine-related fields. To combine our services and pursue high-value-added business opportunities by standardizing the allocation of management resources and the management structure, we determined that a single reporting segment, the regenerative medicine-related business, was appropriate.」
Following the discontinuation of facial-care device sales, the consumer business was limited to the manufacture and sale of cosmetics leveraging expertise in regenerative medicine-related fields. The reporting segments were therefore changed to a single segment, the regenerative medicine-related business, to standardize the allocation of management resources and the management structure.